Lineage Cell Therapeutics Inc (LCTX) stock is higher by 40.96% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives LCTX stock a score of 79 out of a possible 100.
That rank is chiefly influenced by a fundamental score of 94. In addition to the average rating from Wall Street analysts, LCTX stock has a mean target price of 5.25. This means analysts expect the stock to gain 348.72% over the next 12 months. LCTX's rank also includes a long-term technical score of 81. The short-term technical score for LCTX is 63.
What's Happening with LCTX Stock Today
Lineage Cell Therapeutics Inc (LCTX) stock is lower by -0.85% while the S&P 500 has fallen -1.88% as of 9:53 AM on Wednesday, Oct 28. LCTX has fallen -$0.01 from the previous closing price of $1.18 on volume of 84,815 shares. Over the past year the S&P 500 is higher by 9.55% while LCTX is higher by 40.96%. LCTX lost -$0.24 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Lineage Cell Therapeutics Inc (LCTX) Stock.
